CN101970689A - 炎性肠病的基因表达标志物 - Google Patents

炎性肠病的基因表达标志物 Download PDF

Info

Publication number
CN101970689A
CN101970689A CN2008801258460A CN200880125846A CN101970689A CN 101970689 A CN101970689 A CN 101970689A CN 2008801258460 A CN2008801258460 A CN 2008801258460A CN 200880125846 A CN200880125846 A CN 200880125846A CN 101970689 A CN101970689 A CN 101970689A
Authority
CN
China
Prior art keywords
ibd
expression
human
polypeptide
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2008801258460A
Other languages
English (en)
Chinese (zh)
Inventor
亚历山大·R·阿巴斯
希拉里·克拉克
劳里·迪尔
查尔斯·李斯
科林·L·诺布尔
杰克·萨特桑吉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Edinburgh
Genentech Inc
Original Assignee
University of Edinburgh
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2008/064562 external-priority patent/WO2008147900A2/en
Application filed by University of Edinburgh, Genentech Inc filed Critical University of Edinburgh
Publication of CN101970689A publication Critical patent/CN101970689A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6809—Methods for determination or identification of nucleic acids involving differential detection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN2008801258460A 2007-11-29 2008-11-26 炎性肠病的基因表达标志物 Pending CN101970689A (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US99120307P 2007-11-29 2007-11-29
US60/991,203 2007-11-29
PCT/US2008/064562 WO2008147900A2 (en) 2007-05-22 2008-05-22 Gene expression markers for inflammatory bowel disease
USPCT/US2008/064562 2008-05-22
US19226808P 2008-09-17 2008-09-17
US61/192,268 2008-09-17
PCT/US2008/085045 WO2009073565A2 (en) 2007-11-29 2008-11-26 Gene expression markers for inflammatory bowel disease

Publications (1)

Publication Number Publication Date
CN101970689A true CN101970689A (zh) 2011-02-09

Family

ID=40459795

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2008801258460A Pending CN101970689A (zh) 2007-11-29 2008-11-26 炎性肠病的基因表达标志物

Country Status (9)

Country Link
EP (1) EP2261367A3 (https=)
JP (1) JP2011509071A (https=)
KR (1) KR20110015409A (https=)
CN (1) CN101970689A (https=)
AU (1) AU2008334095A1 (https=)
CA (1) CA2706729A1 (https=)
IL (2) IL206014A (https=)
MX (1) MX2010005893A (https=)
WO (1) WO2009073565A2 (https=)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103336914A (zh) * 2013-05-31 2013-10-02 中国人民解放军国防科学技术大学 一种提取荟萃生物标志物的方法及装置
CN108893488A (zh) * 2018-06-19 2018-11-27 刘志强 一种重组质粒、dna疫苗及其制备方法和应用
CN109477145A (zh) * 2016-07-05 2019-03-15 剑桥企业有限公司 炎症性肠病的生物标志物
CN110241116A (zh) * 2019-05-21 2019-09-17 中国医学科学院放射医学研究所 一种环状rna及在促进dna损伤修复中的应用
CN110577953A (zh) * 2018-06-11 2019-12-17 深圳华大生命科学研究院 基因突变体及其应用
WO2020000436A1 (zh) * 2018-06-29 2020-01-02 深圳市博奥康生物科技有限公司 一种特异靶向人INDO基因的gRNA导向序列及其应用
CN110719960A (zh) * 2017-03-23 2020-01-21 梅哈里医学院 用于诊断和治疗炎性肠病的方法
CN111936508A (zh) * 2018-03-29 2020-11-13 横向知识产权私人有限公司 环肽及其用途
CN119236059A (zh) * 2024-10-11 2025-01-03 广东医科大学附属医院 Pdlim4基因在制备抑制非小细胞肺癌增殖的药物中的应用
CN119798401A (zh) * 2024-12-30 2025-04-11 常州因普迈生物科技有限公司 基于pdzk1ip1蛋白的多肽、抗体及其应用
CN120510912A (zh) * 2025-05-20 2025-08-19 北京大学人民医院 用于溃疡性结肠炎预测计算机装置及计算机可读存储介质

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102639710A (zh) * 2009-07-20 2012-08-15 基因泰克公司 克罗恩病的基因表达标记
EP2486130A1 (en) * 2009-10-06 2012-08-15 Tallinn University Of Technology Inhibition or activation of serine/threonine ulk3 kinase activity
WO2011127351A1 (en) * 2010-04-09 2011-10-13 Exagen Diagnostics, Inc. Biomarkers for ulcerative colitis and crohn's disease
CA2801575A1 (en) * 2010-06-04 2011-12-08 Prometheus Laboratories Inc. Methods for improving inflammatory bowel disease diagnosis
KR101394197B1 (ko) * 2012-08-17 2014-05-30 관동대학교산학협력단 염증성 장 질환과 연관된 단일염기다형성 정보를 제공하는 방법
WO2014139182A1 (en) 2013-03-15 2014-09-18 Shenzhen Hightide Biopharmaceutical, Ltd. Compositions and methods of using islet neogenesis peptides and analogs thereof
EP3186391B1 (en) * 2014-08-28 2020-05-27 The Provost, Fellows, Foundation Scholars, & the other members of Board, of the College of Holy and Undiv. Trinity of Queen Elizabeth near Dublin Methods and kit for identification of cancer
JP6192177B2 (ja) * 2015-05-25 2017-09-06 ヤマサ醤油株式会社 炎症性腸疾患のバイオマーカーとしてのｓ１００ａ９の使用
US11186872B2 (en) * 2016-03-17 2021-11-30 Cedars-Sinai Medical Center Methods of diagnosing inflammatory bowel disease through RNASET2
EP3641778A4 (en) * 2017-06-20 2021-03-31 Meharry Medical College TARGETED DEFA5 ANTIBODY AND TESTING PROCEDURE FOR DIAGNOSIS AND TREATMENT OF INFLAMMABLE INTESTINAL DISEASES
EP3821246A4 (en) * 2018-07-15 2022-06-22 Rambam Med-Tech Ltd. Determining responders to inflammation treatment
US12293809B2 (en) * 2019-08-23 2025-05-06 Insilico Medicine Ip Limited Workflow for generating compounds with biological activity against a specific biological target
JP2021185817A (ja) * 2020-05-29 2021-12-13 独立行政法人国立病院機構 バイオマーカー及びインターフェロンγ関連遺伝子のバイオマーカーとしての使用
WO2025029562A1 (en) * 2023-07-28 2025-02-06 The Johns Hopkins University Dna vaccines for eliciting t cell immunity in the lung

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001029269A2 (en) * 1999-10-21 2001-04-26 Case Western Reserve University Gene expression profiling of inflammatory bowel disease
US20030198640A1 (en) * 1994-11-07 2003-10-23 Human Genome Sciences, Inc. Methods and compositions for treating inflammatory bowel diseases relating to human tumor necrosis factor-gamma-beta
WO2006063133A2 (en) * 2004-12-06 2006-06-15 The Johns Hopkins University Biomarker for inflammatory bowel disease

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2413974A1 (fr) 1978-01-06 1979-08-03 David Bernard Sechoir pour feuilles imprimees par serigraphie
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4318980A (en) 1978-04-10 1982-03-09 Miles Laboratories, Inc. Heterogenous specific binding assay employing a cycling reactant as label
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
ES2096590T3 (es) 1989-06-29 1997-03-16 Medarex Inc Reactivos biespecificos para la terapia del sida.
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
EP0586505A1 (en) 1991-05-14 1994-03-16 Repligen Corporation Heteroconjugate antibodies for treatment of hiv infection
EP0527283B1 (en) 1991-08-12 1997-11-26 Societe Des Produits Nestle S.A. Food composition
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
FI941572L (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
DE69232137T2 (de) 1991-11-25 2002-05-29 Enzon Inc Multivalente antigen-bindende proteine
AU675929B2 (en) 1992-02-06 1997-02-27 Curis, Inc. Biosynthetic binding protein for cancer marker
ATE244763T1 (de) 1992-02-11 2003-07-15 Cell Genesys Inc Erzielen von homozygotem durch zielgerichtete genetische ereignisse
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
EP0656064B1 (en) 1992-08-17 1997-03-05 Genentech, Inc. Bispecific immunoadhesins
US6283761B1 (en) 1992-09-08 2001-09-04 Raymond Anthony Joao Apparatus and method for processing and/or for providing healthcare information and/or healthcare-related information
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
CA2223198A1 (en) 1997-01-14 1998-07-14 Societe Des Produits Nestle S.A. Composition and method for treatment of inflammatory conditions of the gastro-intestinal tract
US20010010924A1 (en) * 1997-03-14 2001-08-02 Keith Charles Deen Tumor necrosis factor related receptor, tr6 polynecleotides
CA2362929A1 (en) * 1999-03-04 2000-09-08 Human Genome Sciences, Inc. Tumor necrosis factor receptors 6.alpha. and 6.beta.
CN101289511A (zh) 2000-04-11 2008-10-22 杰南技术公司 多价抗体及其应用
GB0130955D0 (en) 2001-12-24 2002-02-13 Cancer Res Ventures Expression system
US20030166282A1 (en) 2002-02-01 2003-09-04 David Brown High potency siRNAS for reducing the expression of target genes
US7526387B2 (en) 2003-07-10 2009-04-28 Genomic Health, Inc. Expression profile algorithm and test for cancer prognosis
WO2007081486A2 (en) * 2005-12-15 2007-07-19 Ventria Bioscience Oral administration of defensins to treat intestinal diseases
SI2257643T1 (sl) * 2008-02-19 2018-12-31 The Children's Hospital Of Philadelphia Identifikacija predelov vnetne črevesne bolezni z začetkom v otroštvu in metode za njeno uporabo za diagnozo in zdravljenje te bolezni

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030198640A1 (en) * 1994-11-07 2003-10-23 Human Genome Sciences, Inc. Methods and compositions for treating inflammatory bowel diseases relating to human tumor necrosis factor-gamma-beta
WO2001029269A2 (en) * 1999-10-21 2001-04-26 Case Western Reserve University Gene expression profiling of inflammatory bowel disease
WO2006063133A2 (en) * 2004-12-06 2006-06-15 The Johns Hopkins University Biomarker for inflammatory bowel disease

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CLAUDIO ET AL: "Expression of the genes dualoxidase2,lipocalin 2 and regenerating islet-derived 1 alpha in Crohn’s disease", 《SCAND J GASTROENTEROL》 *
LAWRANCE I C ET AL: "Ulcerative colitis and Crohn"s disease:distinctive gene expression profiles and novel susceptibility candidate genes", 《HUMAN MOLECULAR GENETICS》 *

Cited By (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103336914B (zh) * 2013-05-31 2016-05-25 中国人民解放军国防科学技术大学 一种提取荟萃生物标志物的方法及装置
CN103336914A (zh) * 2013-05-31 2013-10-02 中国人民解放军国防科学技术大学 一种提取荟萃生物标志物的方法及装置
CN109477145A (zh) * 2016-07-05 2019-03-15 剑桥企业有限公司 炎症性肠病的生物标志物
CN109477145B (zh) * 2016-07-05 2021-04-09 剑桥企业有限公司 炎症性肠病的生物标志物
CN110719960A (zh) * 2017-03-23 2020-01-21 梅哈里医学院 用于诊断和治疗炎性肠病的方法
US12281351B2 (en) 2017-03-23 2025-04-22 Meharry Medical College Methods for diagnosing and treating inflammatory bowel disease
CN110719960B (zh) * 2017-03-23 2024-03-08 梅哈里医学院 用于诊断和治疗炎性肠病的方法
CN111936508A (zh) * 2018-03-29 2020-11-13 横向知识产权私人有限公司 环肽及其用途
CN110577953A (zh) * 2018-06-11 2019-12-17 深圳华大生命科学研究院 基因突变体及其应用
CN110577953B (zh) * 2018-06-11 2024-02-20 深圳华大生命科学研究院 基因突变体及其应用
CN108893488A (zh) * 2018-06-19 2018-11-27 刘志强 一种重组质粒、dna疫苗及其制备方法和应用
WO2020000436A1 (zh) * 2018-06-29 2020-01-02 深圳市博奥康生物科技有限公司 一种特异靶向人INDO基因的gRNA导向序列及其应用
CN110241116B (zh) * 2019-05-21 2023-02-07 中国医学科学院放射医学研究所 一种环状rna及在促进dna损伤修复中的应用
CN110241116A (zh) * 2019-05-21 2019-09-17 中国医学科学院放射医学研究所 一种环状rna及在促进dna损伤修复中的应用
CN119236059A (zh) * 2024-10-11 2025-01-03 广东医科大学附属医院 Pdlim4基因在制备抑制非小细胞肺癌增殖的药物中的应用
CN119798401A (zh) * 2024-12-30 2025-04-11 常州因普迈生物科技有限公司 基于pdzk1ip1蛋白的多肽、抗体及其应用
CN119798401B (zh) * 2024-12-30 2025-10-10 常州因普迈生物科技有限公司 基于pdzk1ip1蛋白的多肽、抗体及其应用
CN120510912A (zh) * 2025-05-20 2025-08-19 北京大学人民医院 用于溃疡性结肠炎预测计算机装置及计算机可读存储介质

Also Published As

Publication number Publication date
EP2261367A2 (en) 2010-12-15
EP2261367A3 (en) 2011-03-23
WO2009073565A3 (en) 2009-09-24
IL233432A0 (en) 2014-08-31
AU2008334095A1 (en) 2009-06-11
AU2008334095A2 (en) 2010-07-15
IL206014A0 (en) 2010-11-30
MX2010005893A (es) 2011-03-04
JP2011509071A (ja) 2011-03-24
KR20110015409A (ko) 2011-02-15
WO2009073565A2 (en) 2009-06-11
CA2706729A1 (en) 2009-06-11
IL206014A (en) 2014-07-31

Similar Documents

Publication Publication Date Title
EP2261367A2 (en) Gene expression markers for inflammatory bowel disease
US20110033486A1 (en) Gene expression markers for crohn's disease
US20140179620A1 (en) Gene expression markers for inflammatory bowel disease
US20090186034A1 (en) Gene expression markers for inflammatory bowel disease
US20190316198A1 (en) Compositions and methods for diagnosis and prediction of solid organ graft rejection
EP1934377B1 (en) Methods for identifying biomarkers useful in diagnosis of biological states
ES2824108T3 (es) Método para identificar receptores de aloinjertos de riñón en riesgo de lesión crónica
WO2015118353A1 (en) Molecular diagnostic test for predicting response to anti-angiogenic drugs and prognosis of cancer
CN104160039B (zh) 川崎病的生物标志物
WO2020104705A9 (en) Predicting a treatment response in inflammatory bowel disease
US20140037618A1 (en) Method of treating autoimmune inflammatory disorders using il-23r loss-of-function mutants
US20250101517A1 (en) Identification of unique blood-based gene expression profiles in children with regressive autism spectrum disorder (asd) and ileocolitis
US20090155788A1 (en) Gene expression markers for inflammatory bowel disease
WO2008079406A2 (en) Gene expression markers for inflammatory bowel disease
JP2008539728A (ja) 膀胱癌バイオマーカーおよびその使用
JP2024536166A (ja) 潰瘍性大腸炎における腸切迫感に関与する遺伝子の抗ｉｌ－２３ｐ１９抗体による調節
US20240301499A1 (en) Method for identifying hard-to-treat osteosarcoma patients at diagnosis and improving their outcome by providing new therapy
HK1174067A (en) Gene expression markers for crohn's disease
KR20180125778A (ko) 차세대서열분석 스크리닝을 통해 발굴한 단일염기다형성에 의한 염증성 장질환의 예측 또는 진단에 관한 정보 제공 방법
HK1116662A (en) Biomarkers for identifying efficacy of tegaserod in patients with chronic constipation

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20110209